Pharmacokinetic Engineering of OX40-Blocking Anticalin Proteins Using Monomeric Plasma Half-Life Extension DomainsMartin Siegemund, Christine Rothe|Frontiers in Pharmacology|2021Cited by 11
Abstract LB135: Simultaneous costimulatory T-cell engagement and checkpoint inhibition by PRS-344/S095012, a PD-L1/4-1BB bispecific compound for tumor localized activation of the immune systemAizea Morales‐Kastresana, Shane A. Olwill, Marina Pavlidou et al.|Cancer Research|2021Cited by 1
Supplementary Table from The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized MannerJanet K. Peper-Gabriel, Shane A. Olwill, Marina Pavlidou et al.|Unknown|2023Cited by 1
Supplementary Figure from The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized MannerJanet K. Peper-Gabriel, Shane A. Olwill, Rachida S. Bel Aiba et al.|Unknown|2023Cited by 0
Supplementary Figure from The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized MannerJanet K. Peper-Gabriel, Shane A. Olwill, Marina Pavlidou et al.|Unknown|2023Cited by 0